A new analysis warns that proposed White House regulations could terminate nearly 5,000 clinical trials, including about 1,000 cancer studies. The report from science advocacy group Stand Up for Science ties the risk to a rule proposed by the Office of Management and Budget (OMB) that would give political appointees final decision-making over federal research grant judgments. The analysis cites downstream effects on pediatric, veteran, heart disease, and international collaboration trials. A 2025 JAMA Internal Medicine analysis is referenced showing that earlier Trump-era grant terminations affected as many as 74,000 patients in the associated trials. The development raises immediate operational uncertainty for trial sponsors and contract research organizations, because late-stage studies depend on predictable funding and grant continuity.